[go: up one dir, main page]

AR032386A1 - Preparaciones de ciclodextrina - Google Patents

Preparaciones de ciclodextrina

Info

Publication number
AR032386A1
AR032386A1 ARP020100001A ARP020100001A AR032386A1 AR 032386 A1 AR032386 A1 AR 032386A1 AR P020100001 A ARP020100001 A AR P020100001A AR P020100001 A ARP020100001 A AR P020100001A AR 032386 A1 AR032386 A1 AR 032386A1
Authority
AR
Argentina
Prior art keywords
ebselen
cyclodextrin
aqueous solution
mixing
dissolving
Prior art date
Application number
ARP020100001A
Other languages
English (en)
Original Assignee
Daiichi Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co
Publication of AR032386A1 publication Critical patent/AR032386A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D293/00—Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms
    • C07D293/10—Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D293/12—Selenazoles; Hydrogenated selenazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provee una solucion acuosa transparente de una cantidad suficiente de ebselen que puede usarse como inyeccion. Una solucion acuosa que comprende ebselen y ciclodextrina. Una inyeccion que comprende dicha solucion acuosa. Una infusion para goteo intravenoso que comprende dicha solucion acuosa. Un proceso para producir una solucion acuosa que contiene ebselen y ciclodextrina, que comprende disolver ebselen en un solvente orgánico miscible en agua mientras se disuelve separadamente ciclodextrina en un solvente acuoso, mezclar ambas soluciones, luego secar la mezcla, y mezclar el producto seco resultante con un solvente acuoso. Una preparacion seca que comprende ebselen y ciclodextrina. Un proceso para producir una solucion que contiene ebselen y ciclodextrina, que comprende disolver ebselen en un solvente orgánico miscible en agua mientras se disuelve separadamente ciclodextrina en un solvente acuoso, y mezclar ambas soluciones.
ARP020100001A 2001-01-04 2002-01-02 Preparaciones de ciclodextrina AR032386A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001000247 2001-01-04
JP2001016022 2001-01-24

Publications (1)

Publication Number Publication Date
AR032386A1 true AR032386A1 (es) 2003-11-05

Family

ID=26607336

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020100001A AR032386A1 (es) 2001-01-04 2002-01-02 Preparaciones de ciclodextrina

Country Status (12)

Country Link
US (1) US20040053888A1 (es)
EP (1) EP1348432A4 (es)
JP (1) JPWO2002055076A1 (es)
KR (1) KR20030068203A (es)
CN (1) CN1492760A (es)
AR (1) AR032386A1 (es)
BR (1) BR0116658A (es)
CA (1) CA2434077A1 (es)
MX (1) MXPA03006071A (es)
NO (1) NO20033042L (es)
RU (1) RU2003119972A (es)
WO (1) WO2002055076A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3457300A (en) 1999-03-31 2000-10-16 Daiichi Pharmaceutical Co., Ltd. Substrates for thioredoxin reductase
CN1853627B (zh) * 2005-04-25 2011-08-10 曾慧慧 双苯并异硒唑乙烷环糊精或环糊精衍生物包合物及其制备方法和其用途
NZ587586A (en) 2005-07-18 2012-04-27 Bipar Sciences Inc Treatment of cancer
JP4886233B2 (ja) * 2005-07-21 2012-02-29 独立行政法人物質・材料研究機構 エブセレンの可溶化方法
CN100503647C (zh) * 2005-11-02 2009-06-24 南京师范大学 羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用
PL1795183T3 (pl) * 2005-12-09 2009-12-31 Teva Pharma Wodne dyspersje i roztwory słabo rozpuszczalnych związków oraz sposoby ich wytwarzania
US20100160442A1 (en) * 2006-07-18 2010-06-24 Ossovskaya Valeria S Formulations for cancer treatment
AU2007292387A1 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
EP2061479A4 (en) 2006-09-05 2010-08-04 Bipar Sciences Inc FETTIC ACID SYNTHESIS INHIBITED BY PARP HEMMER AND TREATMENT PROCEDURES THEREWITH
CN100411688C (zh) * 2006-09-12 2008-08-20 南京师范大学 含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法
CN100486645C (zh) * 2006-09-12 2009-05-13 南京师范大学 含有环糊精紫杉醇包合物的药物组合物及其制备方法
HRP20120960T1 (hr) * 2007-01-16 2012-12-31 Bipar Sciences, Inc. Formulacije za lijeäśenje raka
CA2705537A1 (en) 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
MX2011008221A (es) * 2009-02-04 2011-08-17 Bipar Sciences Inc Tratamiento de cancer de pulmon con un compuesto de nitrobenzamida en combinacion con un inhibidor de un factor de crecimieno.
GB201102248D0 (en) 2011-02-09 2011-03-23 Isis Innovation Treatment of bipolar disorder
RU2451680C1 (ru) * 2011-02-21 2012-05-27 Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" Клатратный комплекс циклодекстрина или арабиногалактана с 9-фенил-симм-октагидроселеноксантеном, способ его получения (варианты), фармацевтическая композиция и лекарственное средство
WO2015042170A1 (en) 2013-09-17 2015-03-26 Wayne State University Compositions and uses of combinations of dim-related indoles and selected anti-androgen compounds
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
US10058542B1 (en) 2014-09-12 2018-08-28 Thioredoxin Systems Ab Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith
US10576086B2 (en) 2015-06-12 2020-03-03 University Of Greenwich Triazine derivatives as interferon-gamma inhibitors
US11400054B2 (en) 2017-06-30 2022-08-02 Industrial Technology Research Institute Method for treating an autoimmune neurological disease and/or neurodegenerative disease and pharmaceutical formulations for a liquid dosage form and a controlled release dosage form
WO2021054863A1 (ru) * 2019-09-18 2021-03-25 Рахимджан Ахметджанович РОЗИЕВ Стимулятор процессов репаративной регенерации тестикулярной ткани
EP4536192A1 (en) * 2022-06-06 2025-04-16 Sound Pharmaceuticals Incorporated Amorphous dosage form containing ebselen
WO2024181358A1 (ja) * 2023-02-27 2024-09-06 国立大学法人東北大学 医薬組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01131113A (ja) * 1987-08-27 1989-05-24 Dai Ichi Seiyaku Co Ltd 脳障害治療剤
US5288734A (en) * 1988-10-29 1994-02-22 A. Nattermann & Cie Gmbh Stable parenteral solution of 2-phenyl-1.2-benzisoselenazol-3(2H)-one and process for producing the same
AU5780696A (en) * 1995-06-02 1996-12-18 Takeda Chemical Industries Ltd. Stabilized composition comprising an antiulcerative benzimid azole
KR20010031520A (ko) * 1997-11-07 2001-04-16 스즈키 다다시 피페라진류-시클로덱스트린 복합체
AU1411600A (en) * 1998-11-30 2000-06-19 Sankyo Company Limited Immunoglobulin preparations

Also Published As

Publication number Publication date
CA2434077A1 (en) 2002-07-18
RU2003119972A (ru) 2004-12-27
NO20033042D0 (no) 2003-07-02
BR0116658A (pt) 2003-12-30
WO2002055076A1 (en) 2002-07-18
JPWO2002055076A1 (ja) 2004-05-13
EP1348432A1 (en) 2003-10-01
CN1492760A (zh) 2004-04-28
MXPA03006071A (es) 2004-02-26
KR20030068203A (ko) 2003-08-19
EP1348432A4 (en) 2005-08-10
US20040053888A1 (en) 2004-03-18
NO20033042L (no) 2003-09-04

Similar Documents

Publication Publication Date Title
AR032386A1 (es) Preparaciones de ciclodextrina
AR048017A1 (es) Composicion y metodo para aumentar la biodisponibilidad
BR112012032770A2 (pt) preparação de solições médicas a partir de material em pó
MX2007004973A (es) Formulacion solida con solubilidad y estabilidad mejoradas y metodo para producir la formulacion.
CR6654A (es) Composiciones farmaceuticas que proporcionan concentraciones potenciadas de farmaco
DK1033973T3 (da) Fremgangsmåde til indkapsling
WO2007146250A3 (en) Naphthalene-based semiconductor materials and methods of preparing and use thereof
UY32761A (es) Preparaciones termoestables y preparaciones insulinicas estables a las vibraciones
GT200900308A (es) "complejos de hierro y derivados de carbohidrato solubles en agua, su produccion y medicamentos que contienen los mismos"
BRPI0413957A (pt) processo para preparar diterpenos solúveis em água, solução aquosa e suas aplicações
CL2009001081A1 (es) Procedimiento para producir un vehiculo en forma de particulas que comprende disolver polibutilcianoacrilado en un disolvente organico para formar una solucion polimerica, anadir una solucion acuosa, mezclar y obtener el vehiculo en forma de particulas; composicion farmaceutica que comprende dicho vehiculo.
AR053737A1 (es) Formulacion pediatrica de topiramato
DK1563041T3 (da) Anvendelse af 2,6-di-tert-butyl-p-cresol til forögelse af lagerstabiliteten af biodiesel
UY28808A1 (es) Un procedimiento para la preparación de composiciones pesticidas nanoparticuladas y composiciones obtenidas a partir de éstas
WO2008016828A3 (en) Efficient carrier injection in a semiconductor device
MXPA05010045A (es) Metodos y aparatos para la fragmentacion y estabilizacion de particulas pequenas.
GT201000102A (es) Producto de dispersión sólida de drogas basadas en n-aril urea
DK1171124T4 (da) Anthelmintpræparater
AR046065A1 (es) Cristales de penam y procedimiento para la produccion de los mismos
AR027016A1 (es) Proceso para la estabilizacion de vino
WO2005097201A3 (fr) Complexes d’inclusions comprenant du piroxicam, une cyclodextrine et l’arginine
TW200639583A (en) Coloring composition
CL2008001650A1 (es) Procedimiento de preparacion de una disolucion de docetaxel en polisorbato 80 que consiste en disolver el docetaxel en un disolvente organico que tiene un punto de ebullicion comprendido entre 40-153 grados celsius, con la excepcion de etanol, se mezcla la disolucion con polisorbato 80, se evapora el disolvente bajo presion reducida.
AR048756A1 (es) Procedimiento para formar atorvastatina amorfa
EP1342706A4 (en) PROCESS FOR PREPARING A MOLECULAR COMPOUND

Legal Events

Date Code Title Description
FB Suspension of granting procedure